Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis publishes positive Onbrez Breezhaler trial data

Novartis publishes positive Onbrez Breezhaler trial data

20th May 2010

Novartis has revealed new clinical data demonstrating the advantages its drug Onbrez Breezhaler can bring to chronic obstructive pulmonary disease (COPD) patients.

The pharmaceutical company presented data from a phase III study which showed that patients trialled using the indacaterol-based drug were less likely to require relief medication than those using tiotropium.

In addition, the trial showed that Onbrez Breezhaler also delivered lung function improvements when compared to placebo, as well as reducing rates of patient COPD exacerbations.

Steffen Roellinger, global head of development at Novartis’ respiratory franchise, said these results will support the company’s efforts to deliver effective respiratory illness therapies.

He added: “The results on indacaterol further support that commitment to patients with COPD.”

Last month, Novartis increased its stake in the RNA interference therapy specialist Alnylam Pharmaceuticals to 13.4 per cent of its common stock, in a move designed to strengthen the firms’ alliance on developing innovative new therapies.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.